- Press Release Distribution

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

( CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven’t experienced improvement with chemotherapy treatments.

But if this CAR-T treatment fails, or the cancer returns yet again — as happens in approximately half of people — the prognosis is dire. The median survival time after relapse is about six months.

Now, a phase 1 clinical trial at Stanford Medicine has found that a new CAR-T cell therapy that targets a different protein on the surface of the cancer cells significantly improved these patients’ outcomes: Over half of 38 people enrolled in the trial — 37 of whom had already relapsed from the original CAR-T therapy — experienced a complete response of their cancers. More than half of all treated patients lived at least two years after treatment.

“On average, the patients enrolled in this trial had received four previous lines of therapy,” said assistant professor of medicine and the trial’s principal investigator Matthew Frank, MD, PhD. “These patients are out of likely curative options, and they are scared. Half of them will die within five to six months. But in this trial, we saw a very high rate of durable complete responses, meaning their cancers became undetectable.”

‘Breakthrough therapy’

The original CAR-T therapy, approved by the Food and Drug Administration in 2017, involves removing immune cells from the patient and inserting a gene to help the cells attack a protein called CD19 on the surface of the lymphoma cells. The new version of the therapy instead targets a molecule called CD22.

In September 2022, the FDA designated CD22-targeting CAR-T therapy for large B-cell lymphoma a Breakthrough Therapy, a move that is meant to speed the development and review of particularly promising drugs that may provide a substantial improvement over existing therapies for serious conditions. 

The study was devised and conducted entirely at Stanford Medicine.

“This trial was an example of what it means to take an idea from preclinical studies in animals all the way into the patient at an academic medical center,” said David Miklos, MD, PhD, professor of medicine and chief of bone marrow transplantation and cellular therapy. “Remarkably, the FDA — after reviewing our preliminary data — contacted us to urge us to apply for breakthrough therapy designation, rather than waiting for us to approach them. This will help us significantly as we move into larger clinical trials.”

A larger, phase 2 trial led by Frank is now ongoing at multiple sites around the country.

Miklos is the senior author of the study, which will be published July 9 in The Lancet. Frank; assistant professor of medicine John Baird, MD; and postdoctoral scholar Anne Kramer, MD, PhD, are the lead authors of the research.

CAR-T cell therapy was first approved by the FDA as a treatment for relapsed or treatment-resistant diffuse large B-cell lymphoma and for children and young adults under 25 with acute lymphoblastic leukemia.

Six CAR-T cell therapies are now approved for several types of lymphoma, multiple myeloma and acute lymphoblastic leukemia. Four of these therapies target CD19, which is found on the surface of healthy and cancerous B cells; two target another protein on the cells’ surface called B cell maturation agent.

CD22 is another protein found on the surface of mature B cells, and researchers have been eying it for some time as a possible second target for CAR-T cell therapy. That’s because, although CAR-T cell therapy targeting CD19 is typically successful, many patients relapse quickly as the cancer cells figure out how to reduce the amounts of CD19 on their surfaces or their engineered immune cells become exhausted from a prolonged attack.

Several trials have experimented with engineering CAR-T cells that recognize both CD19 and CD22 — exploring whether a double volley of attack might eliminate cancer cells before they learn how to evade the treatment.

These efforts have met with mixed success. While more people with acute lymphoblastic leukemia responded to the double-targeted CAR-T therapy, the results for people with lymphoma were more tempered. In a trial conducted at Stanford Medicine, the therapy had some efficacy but was no more effective than targeting CD19 alone. Frank, Miklos and their colleagues wondered what would happen if only CD22 were targeted.

A new target

The researchers collected immune cells called T cells from 38 patients with large B-cell lymphoma whose cancers had started growing after previous therapies including chemotherapy. All but one of the patients had also progressed after CAR-T therapy targeting CD19; the cancer cells of the one remaining patient did not express CD19 on their surfaces.

The T cells were grown and genetically engineered to target CD22 in Stanford Medicine’s Laboratory for Cell and Gene Medicine in partnership with the Center for Cancer Cell Therapy. They were then infused back into the patients from whom they were derived.

Of the 38 patients, 68% saw their cancers shrink, and 53% achieved a complete response, meaning their cancers were no longer detectable.

“This is not just a high response rate, but many of these remissions have been quite durable over a median of 30 months of follow-up,” Frank said. “If this holds true in larger trials, it will surpass other therapeutic option we have for these patients.” Additionally, most patients experienced minimal, manageable side effects.

The results of the trial are the first in a series of hurdles CD22-targeted CAR-T cell therapy will have to clear for it to be approved by the FDA for routine clinical use for those with intractable large B-cell lymphoma. According to Miklos, it also highlights the advantages of intertwining medicine and research.

“We conducted the preclinical studies at Stanford Medicine, translated the findings in our cell manufacturing and cancer cell therapy centers, and cared for the patients here,” Miklos said. “This pipeline allows us to leverage our research and clinical findings in an iterative way. If something is not working, we can refocus and retool our approach to pivot quickly to new approaches to help our patients.”

“It is rare for an academic medical center to attain a breakthrough designation,” Frank noted. “It’s humbling. Larger trials need to be completed, and FDA approval is not guaranteed, but this is a huge achievement for all the members of the team and a hopeful sign for patients and their caregivers.”

Researchers from Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan and Cancer Center Amsterdam, who are currently working at Stanford, contributed to the work.

The study was funded by the National Institutes of Health (grants 2P01CA049605-29A1, 5P30CA124435 and K08CA248968), the Virginia and D.K. Ludwig Fund for Cancer Research, the Parker Institute for Cancer Immunotherapy, the European Hematology Association, the Lymph&Co Foundation, and the Leukemia and Lymphoma Society.

Miklos has consulted for Kite Pharma-Gilead, Juno Therapeutics-Celgene, Novartis, Janssen and Pharmacyclics. Research support from Kite Pharma-Gilead, Allogene, CARGO Therapeutics, Pharmacyclics, Miltenyi Biotec and Adaptive Biotechnologies.

Frank has consulted for Kite Pharma-Gilead, Adaptative Biotechnologies and CARGO Therapeutics; he has also received research support from Kite-Pharma-Gilead, Allogene Therapeutics, Cargo Therapeutics and Adaptative Biotechnologies.

Study co-author Crystal Mackall, MD, the Earnest and Amelia Gallo Family Professor and professor of pediatrics and of medicine, is a founder of CARGO Therapeutics and holds equity in and consults for the company. CARGO holds the license for the CD22-directed CAR-T cell therapy.

# # #


About Stanford Medicine

Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit



Major trial looks at most effective speech therapy for people with Parkinson’s disease

A major clinical trial, led by experts at the University of Nottingham, has shown the Lee Silverman Voice Treatment (LSVT LOUD®) is more effective than the current speech and language therapy provided by the NHS, when treating patients with Parkinson’s disease (PD). The results of the NIHR HTA funded trial, which are published today in the BMJ, showed that LSVT LOUD® was more effective at reducing the participant’s reported impact of voice problems than no speech and language therapy, as well as the NHS delivered speech and language therapy. The trial was led by experts from the Universities of Nottingham and Birmingham, ...

Intensive voice treatment more effective than NHS speech therapy for Parkinson’s disease

An intensive voice treatment developed in the USA and known as the Lee Silverman voice treatment (LSVT LOUD) is more effective than conventional NHS speech and language therapy or no therapy for people with Parkinson’s disease, finds a trial published in The BMJ today. The researchers say the results emphasise the need to optimise the use of speech and language therapy resources for people with Parkinson’s disease. Slurred or slow speech (known as dysarthria) is a common feature of Parkinson’s disease and can have a significant effect ...

NHS’s relentless focus on finance and productivity is failing patient safety

“The NHS’s relentless focus on finance and productivity is failing patient safety,” argues patient safety commissioner Henrietta Hughes in an interview for The BMJ today. “The patient’s anecdote is the canary in the coal mine,” she says. It’s the thing that tells us there’s something going wrong. But too often we hear about patients who have raised concerns being gaslighted, dismissed, and fobbed off.” Hughes, a GP and former medical director at NHS England, became England’s first independent patient safety commissioner in September 2022. The job was created ...

World leaders unite to embed social participation in health systems

For the first time in the World Health Organization’s 76 year history, world leaders have unanimously committed to put social participation - people, communities and civil society - at the heart of health decision making processes. This landmark pledge marks an important step forward in creating a healthy world, say experts in The BMJ today, and they urge everyone to seize their right to influence the decisions that affect their health and well-being. Global challenges such as access to care, climate change, widening ...

AI Chatbots have shown they have an ‘empathy gap’ that children are likely to miss

Artificial intelligence (AI) chatbots have frequently shown signs of an “empathy gap” that puts young users at risk of distress or harm, raising the urgent need for “child-safe AI”, according to a study. The research, by a University of Cambridge academic, Dr Nomisha Kurian, urges developers and policy actors to prioritise approaches to AI design that take greater account of children’s needs. It provides evidence that children are particularly susceptible to treating chatbots as lifelike, quasi-human confidantes, ...

Dante on the Move: Refugee’s share experiences through the lens of 14th century poet

Dante on the Move: Refugee’s share experiences through the lens of 14th century poet
International refugees and academic experts have contributed to a new book examining the resonance of Dante’s Divine Comedy with today’s migrants fleeing the troubles in their home countries. Dante on the Move is launched in Rome today (Thursday 11th July) and has been produced as part of a research project Reading Dante with Refugees led by the University of Birmingham and Trinity College Rome. It features work by people from Afghanistan, China, Egypt, Iran, Iraq, Kurdistan, Ukraine, the USA and Venezuela. Mohammed, a Kurdish refugee from Iraqi and contributor to the book survived a shipwreck in the Mediterranean in which many people drowned. He said: “Reading ...

Loneliness increases risk of age-related memory loss

About a third of Canadians feel lonely, and a study from the University of Waterloo shows it has a greater negative impact on memory than even social isolation, though both present a significant risk to the aging population. Loneliness is a subjective emotion that people might feel even while engaging in social activities. It is often associated with depression and an increase in stress hormones that may contribute to impaired memory. Waterloo researchers examined four combinations of social isolation ...

Study: Nanoparticle vaccines enhance cross-protection against influenza viruses

Study: Nanoparticle vaccines enhance cross-protection against influenza viruses
ATLANTA — To offer cross-protection against diverse influenza virus variants, nanoparticle vaccines can produce pivotal cellular and mucosal immune responses that enhance vaccine efficacy and broaden protection, according to a study by researchers in the Institute for Biomedical Sciences at Georgia State University. The study, published in the journal Nature Communications, offers valuable insights into tailoring immunization strategies to optimize influenza vaccine effectiveness. To alleviate the significant ...

Student leadership development requires holistic approach, educators say

Student leadership development requires holistic approach, educators say
URBANA, Ill. – Colleges and universities often highlight leadership development as a critical component of their curriculum — but there is no clear consensus on what constitutes effective leadership education. In a new paper, two educators from the University of Illinois Urbana-Champaign and John Carroll University provide a roadmap for training competent leaders, suggesting a comprehensive, practical approach for postsecondary institutions to follow. “Our purpose was to discuss what it means to develop leaders and what a model for leadership education could ...

Mars likely had cold and icy past, new study finds

Mars likely had cold and icy past, new study finds
The question of whether Mars ever supported life has captivated the imagination of scientists and the public for decades. Central to the discovery is gaining insight into the past climate of Earth’s neighbor: was the planet warm and wet, with seas and rivers much like those found on our own planet? Or was it frigid and icy, and therefore potentially less prone to supporting life as we know it? A new study finds evidence to support the latter by identifying similarities between soils found on Mars and those of Canada’s Newfoundland, a cold subarctic climate. The study, published July 7th in Communications Earth and Environment, looked for soils on Earth with ...


Samuel Pepys’ fashion prints reveal his guilty pleasure: Fancy French clothes

New genetic test will eliminate a form of inherited blindness in dogs

Cancer risk: Most Australian welders exposed to high levels of dangerous fumes

Two-in-one mapping of temperature and flow around microscale convective flows

Texas A&M engineers explore intelligence augmentation to improve safety

ORNL economist honored at international hydropower conference

UCLA selected by Centers for Medicare & Medicaid Services to test Medicare dementia care model

Fish adjust reproduction in response to predators

DDX41 and its unique contribution to myeloid leukemogenesis

Digital games on vaping devices could lure more youth to nicotine addiction

Cracking the code of hydrogen embrittlement

Long-term results from Testicular Cancer treatment are positive, study shows

EPA awards UMass Amherst nearly $6.4 million to help shrink the steel industry’s carbon footprint

Valentina Greco takes on new position as President of the ISSCR

Komen supports UVA Engineering researchers targeting ‘triple negative' breast cancer

Panel issues first guidelines to prevent anal cancer in people with HIV

Estimating rainfall intensity using surveillance audio and deep-learning

Targeting factors for chemoprevention and cancer interception to tackle mesothelioma

New snake discovery rewrites history, points to North America’s role in snake evolution

Large and unequal life expectancy declines in India during COVID-19

A study of 156,000 UK residents found that urban residents score the lowest in social and economic satisfaction and well-being

Global study by Hawaiʻi Institute of Marine Biology demonstrates benefit of marine protected areas to recreational fisheries

Researchers clarify how soft materials fail under stress

Revolutionizing the abilities of adaptive radar with AI

Plastic waste can now be converted to electronic devices

Health equity scholar Darrell Hudson named Health Behavior and Health Education chair at the University of Michigan School of Public Health

Research will establish best ‘managed retreat’ practices for communities faced with climate change disaster

Marshall University awarded grant to further fentanyl addiction research

Wash U researchers shine light on amyloid architecture

New dawn for space storm alerts could help shield Earth's tech

[] Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation